Scientists find protein potential drug target for treatment-resistant prostate cancer

Scientists at Jefferson’s Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely difficult-to-treat cancer.

In addition, the researchers, led by Marja Nevalainen, M.D., Ph.D., associate professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University, also showed that the convergence of two biological pathways could be responsible for making such hormone-resistant prostate cancers especially dangerous.

They have found that a synergy between Stat5 and hormone receptors in recurrent prostate cancer cells helps each maintain its activity. Dr. Nevalainen and her co-workers report their findings January 1, 2008 in the journal Cancer Research.

“These findings validate Stat5 as a potential drug target in prostate cancer, and in particular, in a form of prostate cancer for which there are no effective therapies,” Dr. Nevalainen says.

Men with primary prostate cancer usually have either surgery or radiation, whereas subsequent disease is frequently treated by hormone therapy. But if the cancer recurs again, years later, it can be more aggressive and typically fails to respond to hormone treatment. In previous work, the researchers showed that when Stat5 is turned on in primary prostate cancer, men are more likely to have recurrent disease.

In the current study, the team examined human prostate cancer cells of 198 patients with prostate cancer recurrence. They found that Stat5 was active in 74 percent of all recurrent prostate cancers. Of these patients, 127 had been treated with androgen deprivation therapy. The researchers found Stat5 was active in 95 percent of these hormone resistant tumors, meaning it was more likely to be active if the patient had been treated with hormone deprivation therapy.

Dr. Nevalainen shows that Stat5 interacts with the androgen receptors and keeps them “transcriptionally active.” Next, the scientists would like to conduct tests in animal models to see if this synergy promotes androgen-independent prostate tumor growth, and whether or not Stat5 synergizes with androgen receptors activated by adrenal androgens, which are present in the absence of testicular androgens during the hormone therapy of prostate cancer in patients.

Source: Thomas Jefferson University

Related stories:

Blocking protein kills prostate cancer cells, inhibits tumor growth
Researchers at Jefferson’s Kimmel Cancer Center in Philadelphia have shown that they can effectively kill prostate cancer cells in both the laboratory and in experimental animal models by blocking a signaling protein that is key to the cancer’s growth. The work proves that the protein, Stat5, is both vital to prostate cancer cell maintenance and that it is a viable target for drug therapy.
Cellular senescence a double-edged sword
Scientists have identified a molecular cause behind the ravages of old age and in doing so have also shown how a natural process for fighting cancer in younger persons can actually promote cancer in older individuals. Cellular senescence, the process by which biological cells stop dividing in response to stress or damage to their DNA, was shown to trigger the secretion of proteins that cause inflammation in neighboring cells and tissue. Inflammation is linked to almost every major disease associated with aging, including many cancers.
Broccoli compound targets key enzyme in late-stage cancer
(PhysOrg.com) -- An anti-cancer compound found in broccoli and cabbage works by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a University of California, Berkeley, study appearing this week in the online early edition of the journal Proceedings of the National Academy of Sciences.
Prostate cancer drug reduces testosterone levels in as little as 3 days
More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.
Drop in cancer deaths tied primarily to gains in behavior and screening
Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University.
Prostate cancer spurs new nerves
Prostate cancer – and perhaps other cancers – promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.
Nationwide study confirms PET as the most powerful imaging tool in cancer management
With the most recent release of data from the National Oncologic PET Registry (NOPR), researchers may have reached the moment of critical mass by confirming the effectiveness of positron emission tomography (PET) in the monitoring of tumor activity across a wide range of cancers.
Scientists show how a protein that determines cell polarity prevents breast cancer
In breast tissue, cells lining the breast's ducts have a certain shape that is required to maintain both organ structure and function. All breast cancers display a loss of this characteristic organization, but very little is known about the molecules and pathways that regulate tissue structure and the role they play during cancer.

News discussion:

Medicine & Health news